

MEETING ABSTRACTS

THE HEPATOTOXICITY OF HELENALIN IN DIFFERENTIATED HEPARG CELLS

Michaela Šadibolová ¹, Gabriela Svobodová ¹, Ehiofomwan Ameze Omwanghe ¹, Juraj Lenčo ², Iva Boušová ¹ Presenting author: Michaela Šadibolová (sadibolm@faf.cuni.cz)

- Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, The Czech Republic
- ² Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, The Czech Republic

Helenalin (HEL) is a sesquiterpene lactone used as an antiphlogistic in European and Chinese folk medicine. Its characteristic anti-inflammatory activity is mediated by direct alkylation of Cys38 within the DNA binding domain of NF- κ B subunit p65/RelA. In addition, HEL is a broad-spectrum active compound, featuring an antitumor, antibacterial, and antiprotozoal activity. Recently, a new interest in the biological and pharmacological activities of HEL or its synthetic analogs has been observed (1). HEL has been found to undergo oxidative as well as reductive biotransformation in human liver. In addition, HEL acted as a mechanism-based inhibitor of human cytochrome P450 enzymes (2). Yet, information concerning its potential hepatotoxicity in human is limited. To address this issue, the hepatotoxic effect of HEL was studied in differentiated HepaRG cells that represent a human hepatocytes-like model. Firstly, the cytotoxic effect of HEL was determined using neutral red uptake (NRU) and MTT assay. After 72-hour incubation, the half-maximal inhibitory concentration (IC $_{50}$) of HEL was 13 μ M and 11 μ M using NRU and MTT assay, respectively. Secondly, the pro-oxidant activity of HEL was assessed using oxidant-sensitive probe. HEL was found to increase the formation of reactive oxygen species in a time- and concentration-dependent manner. Thirdly, a comprehensive proteomic analysis using isobaric labeling was performed to study the changes in hepatic proteome upon HEL treatment.

This study was supported by the Charles University Grant Agency (grant No. GAUK 1302120).

Keywords: helenalin; HepaRG; hepatotoxicity; reactive oxygen species; proteomics

References

- 1. Drogosz J, Janecka A. Helenalin A Sesquiterpene Lactone with Multidirectional Activity. Current Drug Targets. 2019;20(4):444-452.
- 2. Šadibolová M, Juvonen RO, Auriola S, Boušová I. *In vitro* metabolism of helenalin and its inhibitory effect on human cytochrome P450 activity. Archives of Toxicology. 2022;96(3):793–808.